title: Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: the CORGI-L Study.
abstract: OBJECTIVE
  This study assessed radiotherapy combined with capecitabine and oxaliplatin in patients with primary, inextirpable colorectal adenocarcinoma.
  
  
  METHODS
  Forty-nine patients entered the trial. Two cycles of XELOX (capecitabine 1000 mg/m(2) bid d1-14+oxaliplatin 130 mg/m(2) d1, q3w) were followed by radiotherapy (50.4 Gy), combined with capecitabine 825 mg/m(2) bid every radiotherapy day and oxaliplatin 60 mg/m(2) once weekly. The primary end-point was objective response.
  
  
  RESULTS
  Forty-seven patients were evaluable. Twenty-nine (62% [95% CI: 46-75%]) achieved complete or partial response. Thirty-eight (81%) went through surgery of whom 37 (97%) had an R0 resection and five (13%) had a pathological complete response. Seventy-eight percent were alive and estimated local progression rate was 11% at 2 years. The most common grade 3+ toxicity during chemoradiotherapy was diarrhoea (24%).
  
  
  CONCLUSIONS
  XELOX-RT was feasible and showed promising efficacy when treating patients with primary inextirpable colorectal cancer, establishing high local control rate.
authors.affiliation: Department of Oncology, Lund University Hospital, Lasarettsgatan, Lund, Sweden. adalsg@hotmail.com
authors.forename: Adalsteinn
authors.initials: A
authors.lastname: Gunnlaugsson
authors.forename: Harald
authors.initials: H
authors.lastname: Anderson
authors.forename: Eva
authors.initials: E
authors.lastname: Fernebro
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Kjellén
authors.forename: Per
authors.initials: P
authors.lastname: Byström
authors.forename: Ke
authors.initials: K
authors.lastname: Berglund
authors.forename: Mats
authors.initials: M
authors.lastname: Ekelund
authors.forename: Lars
authors.initials: L
authors.lastname: Påhlman
authors.forename: Torbjörn
authors.initials: T
authors.lastname: Holm
authors.forename: Bengt
authors.initials: B
authors.lastname: Glimelius
authors.forename: Anders
authors.initials: A
authors.lastname: Johnsson
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000069287:Capecitabine; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D003131:Combined Modality Therapy / Q000379:methods; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010071:Oxaloacetates; D010349:Patient Compliance; D018579:Patient Selection; D011882:Radiotherapy, High-Energy; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D010071:Oxaloacetates; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil